# Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI

> **NCT00517192** · PHASE3 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 40 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Tipranavir
- **DRUG:** Darunavir
- **DRUG:** Ritonavir

## Key facts

- **NCT ID:** NCT00517192
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09
- **Primary completion:** 2008-09
- **Final completion:** —
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00517192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00517192, "Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00517192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*